Australia · Delayed Price · Currency is AUD Adheris Health Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw lower revenue and margins, but cost reductions and digital expansion are driving a return to stability. Cash flow is targeted to be neutral in Q4, with profitability expected in FY 2027 and no need for new capital.
-
Q1 saw significant revenue and margin declines due to regulatory delays, policy pressures, and market headwinds, especially in vaccines. The business is now focused on U.S. transformation, cost optimization, and digital innovation, with specialty medications expected to drive future growth.
Fiscal Year 2025
-
The meeting addressed a challenging year marked by a statutory loss, ANZ divestiture, and U.S. revenue decline. Strategic priorities include cost reduction, digital expansion, and product innovation. All resolutions were put to a poll, with results to be announced to the ASX.
-
The meeting addressed 14 resolutions, with notable shareholder protest votes against executive incentives and retention benefits. Key risks discussed included executive retention and morale, with the Chair emphasizing transparency and the need for stability during strategic changes.
-
FY 2025 results were impacted by U.S. program delays and industry headwinds, leading to a revenue decline and revised guidance. The ANZ business was sold, strengthening the balance sheet, while FY 2026 targets 15% revenue growth and reduced costs amid ongoing strategic review.
-
A strategic review led to the sale of the ANZ business for up to AUD 42.35 million, eliminating debt and leaving a strong cash position. The U.S. business is now the focus, with ongoing review and growth initiatives, and the Board is considering capital management options.
-
Revenue and gross profit fell sharply in 3Q FY25 due to U.S. headwinds, but cost reductions and a strong ANZ business underpin a positive outlook. Strategic review and new platform initiatives are expected to drive growth and margin expansion in FY26.
-
First half FY25 revenue declined due to lower US vaccine-related pharma spend, but profitability was maintained and gross margin improved. Transformation 360 restructuring and a strategic review are underway, with a strong pipeline and new platform launches expected in the second half.
-
Revenue and gross profit declined sharply due to U.S. vaccine program delays, but gross margin improved from a favorable product mix. Restructuring and SaaS pricing changes are expected to drive cost savings and revenue growth in H2, with a positive full-year EBITDA outlook.
Fiscal Year 2024
-
The meeting highlighted record revenue and first profit, a refreshed board, and a five-year plan aiming to double revenue by 2028. Strategic initiatives include a cloud-based platform, AI integration, and a formal review to maximize shareholder value. Voting on five resolutions was conducted by poll.